Glenmark's Telma H and Sun Pharma's Ursocol 300 Drugs Declared Spurious by DCGI
Safety Concerns Regarding Medication
The Drugs Controller General of India (DCGI) has recently identified 16 medications, including Glenmark Pharmaceuticals' Telma H and Sun Pharmaceuticals' Ursocol 300, as spurious following rigorous quality and safety tests. The DCGI reported that these drugs failed to meet necessary standards crucial for public health.
Insights on the Drug Quality Testing
The identified spurious medications have raised alarms in the medical community. Pulmosil injection, used for managing pulmonary hypertension, and Pantocid for gastric issues, are part of the medications flagged. These actions stem from a broader initiative by the Central Drugs Standard Control Organisation (CDSCO) to enhance drug safety.
- Glenmark's Telma H - Prescribed for blood pressure.
- Sun Pharma's Ursocol 300 - Used in gallstone treatment.
- Pulmosil Injection - For pulmonary arterial hypertension.
- Pantocid - Addresses gastric problems.
A further investigation is underway to determine the authenticity of the products, with both companies stating that the disputed batches were not manufactured by them. The push for quality assurance in the pharmaceutical industry centers on safeguarding public health.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.